A family history (FH) of colorectal cancer (CRC) in a first degree relative (FDR; parents, siblings, or children) has long been identified as a risk factor for CRC. 1, 2 Approximately 5%-10% of the population have at least 1 affected FDR with CRC. 1, 3 The increased risk of CRC conferred by having a FH is thought to be determined by the number of affected relatives, the age of disease onset in the affected relative, and the closeness or degree of relation. [4] [5] [6] The lifetime risk of CRC is approximately 2-fold increased in those with an affected FDR with CRC. 1, 2, [7] [8] [9] [10] The risk increases to a greater degree in individuals with multiple affected FDRs or when the CRC is diagnosed before age 50. 2, 5, [7] [8] [9] [10] [11] Little is known about how the risk of CRC in individuals with an affected FDR manifests as a subject ages. Current screening recommendations for CRC presume ongoing, increased risk for subjects with 2 affected FDRs or a FDR diagnosed before age 60. Guidelines advise these subjects to undergo colonoscopy screening at 40 years of age or 10 years before the youngest affected FDR, with indefinite, repeated colonoscopy every 5 years. 12, 13 A FH of CRC is also often used to justify more intensive screening and surveillance colonoscopy, albeit with uncertain yield. 14, 15 In the Clinical Outcomes Research Initiative database for example, among subjects with no findings at baseline colonoscopy and a repeated colonoscopy examination within 1 to 5 years (N ¼ 7372), 30.1% of examinations were performed because of a FH of CRC, and significant lesions were detected infrequently. 15 Our aim was to evaluate the effect of FH of CRC on incidence and mortality to CRC in later age, in a cohort where the risk of early onset cancer had passed.
Methods
The Prostate, Lung, Colorectal, and Ovarian (PLCO) cancer screening trial using flexible sigmoidoscopy enrolled men and women 55 to 74 years of age with no history of CRC at 10 screening centers from 1993 to 2001. Individuals were randomized to an intervention or usual care arm. Intervention arm subjects received flexible sigmoidoscopy at baseline and again at year 3 (for those randomized before April 1995) or year 5. Intervention arm subjects also received annual chest radiograph, prostate-specific antigen tests (men only), digital rectal exam (men only), CA125 tests (women only), and transvaginal ultrasonography (women only) for 4 to 6 years. Exclusion criteria included a history of prostate, lung, colorectal, or ovarian cancer. Beginning in 1995, subjects who had undergone colonoscopy, flexible sigmoidoscopy, or barium enema within the prior 3 years were ineligible for enrollment. Details of the trial have been previously published. 16, 17 Demographics and medical history, including FH of cancer, were ascertained via baseline questionnaire administered at enrollment. With respect to FH, the questionnaire asked: "Have your parents, children, brothers, sisters, half-brothers, or halfsisters ever been diagnosed as having any type of cancer (Do not include basal-cell skin cancer)?" For those responding yes, a chart was provided to document the relationship of the relative, the type of cancer, and the age at which the relative received the diagnosis of that cancer.
Incident cancers and deaths were ascertained primarily by a mailed Annual Study Update questionnaire. Medical records pertaining to diagnosed cancers were reviewed, and data for stage, histology, and grade of cancers were abstracted by certified tumor registrars. Information on vital status was supplemented by periodic linkage to the National Death Index. Cause of death was reviewed blinded to study arm, in a formal adjudication process. 18 Subjects were followed for 13 years, until December 31, 2009, death, or loss to follow-up, whichever came first. Screening centers obtained written informed consent from each participant, and the institutional review board approved the PLCO protocol at each center.
Surveillance colonoscopy examination and outcome were assessed in a randomly selected subset of subjects in the intervention arm. Details of that investigation have been described previously. 14, 19 The authors had access to the study data and reviewed and approved the final manuscript.
Statistical Analysis
Family history of CRC was defined as a FDR, that is, a parent, full sibling, or child with CRC. Subjects not completing the FH section of the baseline questionnaire were excluded. CRC incidence rates per 10,000 person-years (PY) of follow-up were computed by CRC FH status; in addition, for subjects with a FH, CRC incidence rates were computed according to the youngest age at diagnosis of CRC in the FDR (<60, 60-70, >70 years of age), and the number of FDRs with CRC. Cox proportional hazards models were used to examine the hazard ratio (HR) for incident CRC with a FH of CRC and for characteristics of the FH; covariates included trial arm, sex, age, history of lower endoscopy or fecal occult blood test in the 3 years preceding enrollment, body mass index, and use of nonsteroidal anti-inflammatory drugs or aspirin. To examine a possible interaction of FH with age (<65 or 65), age was treated as a time-varying covariate in the Cox model; thus, we determined whether FH had a differential HR for incident CRC diagnosed in the age range 55-64 versus incident CRC diagnosed in the age range 65. We also examined interactions of FH with trial arm and sex. Similar analyses were performed for mortality from CRC.
Results
A total of 154,900 subjects were enrolled in PLCO, of whom 144,768 were included on the basis of completed FH Table 2 ). The HRs based on the age at diagnosis in the affected FDR, including subjects with 2 FDR with CRC, were 1.46 (95% CI, 1.17-1.81), 1.33 (95% CI, 1.09-1.63), and 1.15 (95% CI, 0.92-1.44) for subjects with an FDR receiving a diagnosis at <60, 60-70, and >70 years of age, respectively. There was no statistically significant trend (P ¼ .18) toward an increasing risk of CRC with a younger age at diagnosis in the affected FDR.
There was no significant interaction of FH with subjects' age for CRC incidence; FH HRs were 1.56 for age range of 55-64 versus 1.25 for ages 65 (P ¼ .13 for interaction).
Among 538 deaths resulting from CRC, 71 (13.2%) had a FH of CRC. As with CRC incidence, CRC mortality was similarly significantly increased among those with a FH of CRC (HR, 1.31; 95% CI, 1.02-1.69, P ¼ .03) ( Table 3 ). There was no statistically significantly increased risk of CRC mortality among those with 2 affected FDRs compared to those with only 1 (HR, 1.53; 95% CI, 0.7-3.3; P trend ¼ 0.68), but there were only 7 deaths among subjects with 2 affected FDRs ( Table 3 ). There was no statistically significant trend (P ¼ .81) toward an increasing risk of mortality to CRC with younger age at diagnosis in the affected FDR.
FH of CRC was significantly associated with an increased risk of CRC in both men (RR, 1.26; 95% CI, 1.05-1.50, P ¼ .012) and women (HR, 1.35; 95% CI, 1.12-1.63, P ¼ .002) ( Table 4) . Similar point estimates, although not statistically significant for men, were observed for the association of FH and CRC mortality in men (N ¼ 307 deaths, HR, 1.20; 95% CI, 0.8-1.7, P ¼ .3) and women (N ¼ 231 deaths, HR, 1.44; 95% CI, 1.01-2.0, P ¼ .04) (Supplementary Table 1 ). Both men (HR, 1.79; 95% CI, 1.07-3.00) and women (RR 2.27; 95% CI, 1.44-3.57) had a significantly increased risk of CRC incidence with 2 affected FDRs. Men and women also had a similar increased risk of CRC with 1 affected FDR (men: HR, 1.21; 95% CI, 1.00-1.47, women: RR 1.26; 95% CI, 1.03-1.54) ( Table 4 ). Similar trends in men and women were observed for the relationship between the age at diagnosis of the affected FDR and the risk of incident CRC (Table 4) .
Among those with a FH of CRC, there were 56 cases of rectal and 217 cases of colon cancer. FH of CRC in a FDR was significantly associated with the risk of colon cancer (HR, 1.31; 95% CI, 1.41-1.50, P ¼ .0003); a similar HR was observed for rectal cancer, although it was not statistically significant (HR, 1.27; 95% CI, 0.95-1.69, P ¼ .10) (Supplementary Table 2 ). There were no differences in the association of FH with proximal (HR, 1.24; 95% CI, 1.03-1.48) as opposed to distal (HR, 1.36; 95% CI, 1.13-1.64) CRC (Supplementary Table 2 ).
The risk of incident CRC by the age at diagnosis in the FDR was assessed after excluding individuals with 2 affected FDRs, as they were at higher risk (Table 5 ). Defined as positive FH in a first degree relative. c P value is P trend for increasing number of affected FDRs among those with a family history of CRC. When there are more than 1 affected FDRs, the age at diagnosis is the youngest affected FDR. In 7 subjects, the age at diagnosis of CRC in the FDR was unknown. e P value is P trend for increasing age at diagnosis of FDR. These estimates include subjects with 2 FDRs with CRC.
Among individuals with 1 FDR with CRC, there was no difference in risk based on the age at diagnosis in the FDR (HR, 1.27; 95% CI, 0.97-1.63 for subjects with a FDR diagnosed at age <60; HR, 1.33; 95% CI, 1.06-1.62 for subjects with FDR diagnosed between 60 and 70 years; HR, 1.14; 95% CI, 0.93-1.45 for subjects with FDR diagnosed at >70 years of age; P trend ¼ 0.59). Figure 1 demonstrates the cumulative risk of FH-associated CRC over time, stratified by FH risk group. The absolute increase in CRC incidence was 0.33% (95% CI, 0.10-0.56%) for those with 1 affected FDR and 1.6% (95% CI, 0.6-2.6%) for those with 2 affected FDRs.
The FH HRs for both CRC incidence and CRC mortality were similar within each trial arm; 1.27 (95% CI, 1.04-1.5) and 1.53 (95% CI, 1.1-2.2) for incidence and mortality, respectively, in the intervention arm versus 1.33 (95% CI, 1.1-1.6) and 1.15 (95% CI, 0.8-1.6), respectively, for incidence and mortality in the usual care arm (P value for interaction of FH by trial arm equals 0.84 for incidence and 0.73 for mortality). Also, we did not identify a statistically significant interaction between FH of CRC and screening history prior to enrollment (fecal occult blood test or endoscopy) and CRC incidence, P ¼ . 16 .
Because a difference in use of surveillance colonoscopy after screening in subjects with compared to those without a FH of CRC could have affected CRC incidence and mortality, use of surveillance colonoscopy was examined in a randomly selected cohort of subjects (N ¼ 3594) in the intervention arm of the PLCO trial. 14, 19 The use of surveillance colonoscopy by FH and by baseline adenoma findings is shown in Table 6 . At 5 years after baseline colonoscopy, surveillance colonoscopy was used in 7.2% more subjects with a FH of CRC compared to those without a FH (53.9% vs 46.7%, respectively). At 7 years, the difference was 8.8% and 6.6% at 10 years.
Discussion
In our prospective study, we observed a modest 30% increased risk in CRC incidence and mortality in subjects over age 55 with a FH of CRC in a FDR. Subjects with 2 FDRs with CRC were identified as a high-risk group, with a 2-fold increased risk of incident CRC. Within our age cohort, after excluding subjects with 2 FDRs, a young age of onset in the FDR (<60 years at time of diagnosis) was not associated with a differential increased risk in CRC incidence or mortality compared to subjects with FDRs affected at older ages (Table 5) . We observed no differences in risk relationships between a FH of CRC and incident CRC in men compared to women, nor did we observe a stronger relationship between a FH of colorectal cancer and proximal as opposed to distal cancer or colon as opposed to rectal cancer.
A FH of CRC is used to justify more intensive surveillance colonoscopy in subjects with adenomatous polyps, at times in excess of recommended guidelines, 14, 15 although evidence of an increased yield in subjects with a FH is unproven. 20 Given that our data indicate a relatively small increase in cancer incidence or mortality in subjects after age 55 with a FH of CRC, more aggressive surveillance colonoscopy in subjects with a FH of CRC and a history of adenomatous polyps is unlikely to substantially contribute to cancer prevention.
Because CRC incidence as an outcome is potentially subject to lead time and over-diagnosis bias, we also evaluated the relationship of CRC mortality to FH of CRC. CRC mortality occurred in 25.7% of incident cases (538 of 2090), limiting statistical power relative to cancer incidence. A FH of CRC was associated with an increase in CRC mortality (HR ¼ 1.31), similar in magnitude to the increased risk observed for CRC incidence, suggesting a limited impact of lead time or over diagnosis bias to our conclusions. Defined as positive FH in a first degree relative. c P value is P trend for increasing number of affected FDRs among those with a family history of CRC. When there are more than 1 affected FDR, the age at diagnosis is the youngest affected FDR. e P value is P trend for increasing age at diagnosis of FDR. These estimates include subjects with 2 FDRs with CRC.
These data derive from a cancer screening trial, with subsequent colonoscopy surveillance provided by local providers. Our estimates of only a modest difference in CRC incidence and mortality between subjects with a FH of CRC compared to those without could be affected if either the effectiveness of screening or surveillance, or the use of surveillance after screening were significantly different in subjects with compared to those without a FH of CRC. We did not observe a significant difference in the benefit of screening in subjects with a FH of CRC, as the hazard ratios for CRC incidence and mortality were similar in those with and without a FH. We evaluated surveillance colonoscopy in a randomly selected cohort of nearly 4000 subjects in the screening arm of the trial. In clinical practice, one would expect subjects with a FH of CRC to undergo more surveillance colonoscopy. We observed a small increase in surveillance colonoscopy among those with a FH, ranging from 6.6% to 8.2% more use at 5 to 10 years after baseline colonoscopy, an amount that is unlikely to have significantly altered the CRC incidence rates among subjects with a FH in comparison to those without. Furthermore, the benefit of post-polypectomy surveillance colonoscopy on CRC incidence and mortality has not been determined. While randomized trials of CRC screening with stool testing or flexible sigmoidoscopy demonstrate a significant reduction in CRC incidence and mortality, 21 the contribution of surveillance colonoscopy has not been evaluated in a clinical trial. 22 It is even less certain whether post-polypectomy surveillance has a greater effect on outcome in subjects with a FH compared to those without, and in a pooled analysis of multiple trials, there was no difference in detection of advanced adenoma or cancer in subjects with compared to those without a FH. 20 Advantages of these data compared to those previously available should be acknowledged. Most investigations exploring FH-associated CRC risk are retrospective, casecontrol studies. 2, 8, 9 In PLCO, individuals were queried about their FH at enrollment, so recall bias regarding the presence of a FH of cancer was minimized. Incident cancers in PLCO were verified by obtaining confirmatory pathologic documentation. The only other prospective study on FH and incident CRC comes from the combined Nurses' Health Study and Health Professionals Follow-up Study, 1 which followed subjects as young as 30 years old. In that cohort, a FH of CRC in a FDR was associated with a 1.7-fold increased risk of CRC. Only 73 subjects with a FH and CRC were included compared to 273 subjects evaluated here, and the former study included only 45 FH-associated CRC cases over age 55, whereas all of our cases were age 55 or more at enrollment. Thus, the PLCO cohort is by far the largest prospective study on FH associated CRC and is particularly informative of CRC risk among middle-aged and older subjects.
Our data do not address the need or utility of screening subjects prior to age 55 who have a FH of CRC, because the PLCO trial only enrolled subjects age 55 or older and excluded subjects with a history of CRC. Many studies demonstrate a higher risk of colorectal cancer at a young age in subjects with FDRs with CRC diagnosed prior to age 50. 1, 2, 7, 8, 10 Screening these subjects at young ages, such as 10 years prior to age at diagnosis in the FDR, is recommended by guidelines. In the Nurses' Health Study and Health Professionals Follow-up Study prospective cohort study 1 for example, there was a marked increase in CRC risk in younger subjects with a FH of CRC. Subjects <45 years of age with a FH of CRC had a 5-fold increased risk of CRC (N ¼ 5, RR 5.37; 95% CI, 1.98-14.6), compared to those without a FH of CRC.
Our data do address the ongoing risk of incident CRC once the subject has reached age 55, where early onset disease, reflecting a highly penetrant genetic component, has passed. The risk estimate for incident CRC in our cohort (HR ¼ 1.3) differs from that in the Nurses and Health Professionals study cohort (RR ¼ 1.7) and to the preponderance of retrospective studies included in meta-analyses. 2, 7 Our lower hazard ratio is likely attributable to the exclusion in our cohort of young onset cancer cases (occurring prior to age <55), and because retrospective studies may be affected by the selection of controls at lower risk of CRC compared to cases, and due to recall bias which may inflate the recollection of a FH of cancer among cases compared to controls.
A recent population-based, colonoscopy based, case control study in Utah demonstrated an overall increased risk of CRC among FDRs compared to controls (HR ¼ 1.79) and 23 also suggested the increased risk with a FH extended beyond FDR to second degree relatives and first cousins. Those data include CRC cases diagnosed at younger ages, and selection bias could also account for some of the observed difference. Our prospective results differ and suggest that, as subjects with a FH of CRC age, the likelihood of a highly penetrant, heritable cancer risk is low and that screening can be more like that of an average risk individual. A recent prospective evaluation of colonoscopy effectiveness in the Nurses' Health Study and Health Professionals Follow-up Study demonstrated a reduced incidence of CRC in subjects with a FH of CRC who underwent a colonoscopy within 5 years (n ¼ 43, HR, 0.44; 95% CI, 0.30-0.66) compared to those with colonoscopy more than 5 years ago (n ¼ 26, HR, 0.91; 95% CI, 0.55-1.51), and to subjects with a FH of CRC who did not undergo any prior colonoscopy. 24 However, one cannot derive recommendations for the optimal timing of colonoscopy from these findings without accounting for the number of affected FDRs, the age of the individuals, and the age of onset in the affected relatives.
Additional limitations of our study include the fact that the FH information was obtained by self-report and not verified. However, previous investigations have demonstrated accuracy in self-reported FH of CRC. [25] [26] [27] The PLCO population is generally well-educated and predominantly Caucasian, so generalization of these findings to minorities and low income groups may be limited.
In conclusion, individuals with 2 FDR with CRC remain at increased risk for CRC into later age. In contrast, after age 55, subjects with 1 FDR with CRC have only a modest increased risk of CRC incidence and mortality compared to those without a FH. Furthermore, after age 55, there was no difference in risk based on the age at diagnosis in the FDR. Our data suggest that increased screening and surveillance colonoscopy in subjects with a FH of CRC in 1 FDR is unlikely to contribute considerably to cancer prevention after age 55. These findings do not impact decisions on when to begin screening, but do suggest that FH-associated CRC risk is only modestly increased once the risk of early onset cancer has passed. Guidelines and clinical practice for subjects with a FH of CRC should be modified to align CRC testing to risk.
